{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:14:46Z","timestamp":1793726086018,"version":"4.6.1"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.thromres.2023.10.007","type":"journal-article","created":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T00:45:19Z","timestamp":1696985119000},"page":"112-120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A"],"prefix":"10.1016","volume":"231","author":[{"given":"Lars L.F.G.","family":"Valke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J.A.","family":"Verhagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart T.P.M.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Polenewen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole M.A.","family":"Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joop H.","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hassan","family":"Mansouritorghabeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Einas","family":"Elsheikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit M.","family":"Reipert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Turecek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"O'Donnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna R.","family":"Rijpma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saskia E.M.","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Waander L.","family":"van Heerde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Meijer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 6","key":"10.1016\/j.thromres.2023.10.007_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2023.10.007_bb0010","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2013.06.002","article-title":"Hemophilia A in the third millennium","volume":"27","author":"Franchini","year":"2013","journal-title":"Blood Rev."},{"key":"10.1016\/j.thromres.2023.10.007_bb0015","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1046\/j.1365-2516.2003.00802.x","article-title":"Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro","volume":"9","author":"Astermark","year":"2003","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.thromres.2023.10.007_bb0020","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1160\/TH16-01-0049","article-title":"The burden of inhibitors in haemophilia patients","volume":"116","author":"Walsh","year":"2016","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0025","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2003-03-0941","article-title":"Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group","volume":"102","author":"Gringeri","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.10.007_bb0030","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2023.10.007_bb0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0140-6736(93)91593-B","article-title":"Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII","volume":"342","author":"Addiego","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2023.10.007_bb0040","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/hae.13424","article-title":"Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review","volume":"24","author":"Miller","year":"2018","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2023.10.007_bb0045","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.12091","article-title":"Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization","volume":"160","author":"Collins","year":"2013","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2023.10.007_bb0050","first-page":"612","article-title":"Proceedings: a more uniform measurement of factor VIII inhibitors","volume":"34","author":"Kasper","year":"1975","journal-title":"Thromb. Diath. Haemorrh."},{"key":"10.1016\/j.thromres.2023.10.007_bb0055","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1055\/s-0038-1653759","article-title":"The Nijmegen modification of the Bethesda assay for factor VIII:C inhibitors: improved specificity and reliability","volume":"73","author":"Verbruggen","year":"1995","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0060","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1055\/s-0037-1615080","volume":"79","author":"Giles","year":"1998","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0065","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0070","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1365-2516.2006.01333.x","article-title":"Pharmacokinetics of recombinant factor VIII (Kogenate-FS) in children and causes of inter-patient pharmacokinetic variability","volume":"12","author":"Barnes","year":"2006","journal-title":"Haemophilia"},{"key":"10.1016\/j.thromres.2023.10.007_bb0075","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1046\/j.1365-2141.1996.d01-1705.x","article-title":"High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII","volume":"93","author":"Dazzi","year":"1996","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.thromres.2023.10.007_bb0080","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1538-7836.2012.04645.x","article-title":"Low-titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half-life after immune tolerance induction","volume":"10","author":"Dardikh","year":"2012","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0085","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1093\/ajcp\/77.6.749","article-title":"In vitro detection of mild inhibitors to factor VIII in hemophilia","volume":"77","author":"Ewing","year":"1982","journal-title":"Am. J. Clin. Pathol."},{"key":"10.1016\/j.thromres.2023.10.007_bb0090","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ajh.24777","article-title":"Acquired hemophilia A: updated review of evidence and treatment guidance","volume":"92","author":"Kruse-Jarres","year":"2017","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.thromres.2023.10.007_bb0095","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1182\/blood-2014-07-587089","article-title":"Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01\/2010 study","volume":"125","author":"Tiede","year":"2015","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2023.10.007_bb0100","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood.2020006315","article-title":"Emicizumab for the treatment of acquired hemophilia A","volume":"137","author":"Knoebl","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.10.007_bb0105","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood.V95.2.558","article-title":"Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes","volume":"95","author":"van Den Brink","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.10.007_bb0110","series-title":"Protocols for Determination of Limits of Detection and Limits of Quantitation, Approved Guideline. CLSI Document EP17","author":"CLSI","year":"2004"},{"key":"10.1016\/j.thromres.2023.10.007_bb0115","series-title":"Preliminary Evaluation of Quantitative Clinical Laboratory Measurement Procedures; Approved Guideline\u2014Third Edition. CLSI document EP10","author":"CLSI","year":"2006"},{"key":"10.1016\/j.thromres.2023.10.007_bb0120","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jtha.2023.01.013","article-title":"Heterogeneity in the half-life of factor VIII concentrate in patients with hemophilia A is due to variability in the clearance of endogenous von Willebrand factor","volume":"21","author":"Elsheikh","year":"2023","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0125","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1182\/blood-2012-07-444877","article-title":"Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients","volume":"121","author":"Whelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.10.007_bb0130","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1182\/blood-2015-10-675512","article-title":"FVIII-binding IgG modulates FVIII half-life in patients with severe and moderate hemophilia A without inhibitors","volume":"128","author":"Hofbauer","year":"2016","journal-title":"Blood."},{"key":"10.1016\/j.thromres.2023.10.007_bb0135","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1111\/jth.15106","article-title":"Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: combining thrombin and plasmin generation","volume":"18","author":"Valke","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.thromres.2023.10.007_bb0140","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1111\/bcp.15185","article-title":"Combining factor VIII levels and thrombin\/plasmin generation: a population pharmacokinetic-pharmacodynamic model for patients with haemophilia A","volume":"88","author":"Bukkems","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.thromres.2023.10.007_bb0145","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1182\/blood-2014-09-598268","article-title":"Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans","volume":"125","author":"Hofbauer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2023.10.007_bb0150","doi-asserted-by":"crossref","first-page":"5785","DOI":"10.1182\/bloodadvances.2020002731","article-title":"The prospective Hemophilia Inhibitor PUP Study reveals distinct antibody signatures prior to FVIII inhibitor development","volume":"4","author":"Reipert","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.thromres.2023.10.007_bb0155","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/ijlh.14109","article-title":"International Council for Standardization in Haematology recommendations for laboratory measurement of factor VIII and FIX type I inhibitors","volume":"45","author":"Meijer","year":"2023","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.thromres.2023.10.007_bb0160","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2011-07-360594","article-title":"Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight","volume":"119","author":"Bjorkman","year":"2012","journal-title":"Blood."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823002840?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384823002840?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:52:07Z","timestamp":1758736327000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384823002840"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":32,"alternative-id":["S0049384823002840"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2023.10.007","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Nijmegen ultra-sensitive Bethesda Assay detects very low-titer factor VIII inhibitors in patients with congenital and acquired hemophilia A","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2023.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}